Coccidioidomycosis cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) No edit summary |
Aditya Ganti (talk | contribs) |
||
| Line 3: | Line 3: | ||
{{CMG}}:{{AE}}{{ADG}} | {{CMG}}:{{AE}}{{ADG}} | ||
==Overview== | ==Overview== | ||
Given the morbidity and mortality associated with coccidioidomycosis infection, and the low cost of safe and effective antifungals, current pharmacotherapy to treat coccidioidomycosis is relatively cost-effective. | Given the morbidity and mortality associated with coccidioidomycosis infection, and the low cost of safe and effective antifungals, current pharmacotherapy to treat coccidioidomycosis is relatively cost-effective.<ref name="pmid26739609">{{cite journal |vauthors=Stockamp NW, Thompson GR |title=Coccidioidomycosis |journal=Infect. Dis. Clin. North Am. |volume=30 |issue=1 |pages=229–46 |year=2016 |pmid=26739609 |doi=10.1016/j.idc.2015.10.008 |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 18:35, 29 March 2017
|
Coccidioidomycosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coccidioidomycosis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Coccidioidomycosis cost-effectiveness of therapy |
|
Coccidioidomycosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Coccidioidomycosis cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]:Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Given the morbidity and mortality associated with coccidioidomycosis infection, and the low cost of safe and effective antifungals, current pharmacotherapy to treat coccidioidomycosis is relatively cost-effective.[1]
References
- ↑ Stockamp NW, Thompson GR (2016). "Coccidioidomycosis". Infect. Dis. Clin. North Am. 30 (1): 229–46. doi:10.1016/j.idc.2015.10.008. PMID 26739609.